p16/CDKN2A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer

American Journal of Clinical Pathology

Volumn 143, Issue 6, 2015, Pages 830-838

  Ito, Tomohiro ^a   Hamasaki, Makoto ^a   Matsumoto, Shinji ^a   Hiroshima, Kenzo ^b   Tsujimura, Tohru ^c   Kawai, Toshiaki ^d   Shimao, Yoshiya ^e   Marutsuka, Kousuke ^f   Moriguchi, Sayaka ^f   Maruyama, Riruke ^g   Miyamoto, Shingo ^a   Nabeshima, Kazuki ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tokyo Women s Medical University   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^f UNIVERSITY OF MIYAZAKI   (Japan)

^g SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

9p21; Diffuse malignant peritoneal mesothelioma; Epithelial ovarian cancer; Fluorescence in situ hybridization; P16; Reactive mesothelial hyperplasia

Indexed keywords

ADULT; AGED; ARTICLE; CDKN2A GENE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; REACTIVE MESOTHELIAL HYPERPLASIA; SENSITIVITY AND SPECIFICITY; GENETICS; MESOTHELIOMA; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR GENE;

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENES, P16; HUMANS; HYPERPLASIA; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84937965062     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPOATJ9L4GCGDA     Document Type: Article

References (38)

1. Hesdorffer ME, Chabot J, DeRosa C, et al. Peritoneal mesothelioma. Curr Treat Options Oncol. 2008;9:180-190.
2. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985-990.
3. Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses: a report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol. 1996;20:1067-1080.
4. Mani H, Merino MJ. Mesothelial neoplasms presenting as, and mimicking, ovarian cancer. Int J Gynecol Pathol. 2010;29:523-528.
5. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and BCL-2. Histopathology. 2003;43:231-238.
6. Hasteh F, Lin G. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118:90-96.
7. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21:742-747.
8. Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855-1863.
9. Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;2:686-691.
10. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systemic review of clinical management and biological research. J Surg Oncol. 2011;103:822-831.
11. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54:5547-5551.
12. Xio S, Li D, Vijg J, et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995;11:511-515.
13. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer. 1998;75:649-653.
14. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006;170:9-15.
15. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and p16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970-2979.
16. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99:51-56.
17. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627-635.
18. Onofre FB, Onofre AS, Pomjanski N, et al. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114:204-215.
19. Takeda M, Kasai T, Enomoto Y, et al. 9p21 Deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60:395-399.
20. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010;138:137-144.
21. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63:630-634.
22. Krasinskas AM, Bartlett DL, Cieply K, et al. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23:531-538.
23. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Anat Pathol. 2011;135:619-627.
24. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic utility of p16/CDKN2A FISH in distinction between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013,139:39-46.
25. Matsumoto S, Nabeshima K, Kamei T, et al. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol. 2013;121:415-422.
26. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
27. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457-1467.
28. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2012;136:1-21.
29. Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87-95.
30. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002;40:237-244.
31. Comin CE, Saieva C, Messerini L. h-Caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139-1148.
32. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
33. Fujita M, Enomoto T, Haba T, et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer. 1997;74:148-155.
34. Hatta Y, Hirama T, Takeuchi S, et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol. 1995;154:1954-1957.
35. Luo Y, Tian L, Feng Y, et al. The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2013;19:35-40.
36. DeHaan RD, Kipp BR, Smyrk TC, et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Human Pathol. 2007;38:491-499.
37. Bosman FT, Carneiro F, Hruban RH. World Health Organization Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010.
38. Ordonez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44:1-19.